sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer), Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies,...

Home / Categories / Healthcare
Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer), Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022
Cancer Biomarkers Market by Profiling...
Report Code
RO1/113/1088

Publish Date
25/Nov/2024

Pages
172
PRICE
$ 5540/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 6654/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 9280/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
TABLE 1 CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES
TABLE 2 WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES (2012)
TABLE 3 REVENUE GENERATION OF BIOLOGICAL AND TARGETED DRUGS IN 2013 ($MILLION)
TABLE 4 KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES
TABLE 5 COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGS
TABLE 6 PATENTS REGISTERED/APPROVED IN THE U.S., EUROPE, CANADA, CHINA, JAPAN, AND OTHERS, 2013 THROUGH 2016
TABLE 7 U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 8 EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 9 CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016
TABLE 10 CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016
TABLE 11 JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 12 OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 13 CLINICAL TRIALS: CANCER BIOMARKERS
TABLE 14 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 15 WORLD OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 16 WORLD OMICS TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 GLOBAL GENOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 1 GLOBAL PROTEOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 2 GLOBAL OTHER OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 3 GLOBAL IMAGING TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 4 GLOBAL IMAGING TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 5 GLOBAL IMMUNOASSAYS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 6 GLOBAL IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 7 GLOBAL CYTOGENETICS-BASED TESTS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 8 GLOBAL CYTOGENETICS-BASED TESTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9 GLOBAL CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 10 GLOBAL GENETIC BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 GLOBAL PROTEIN BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 GLOBAL GLYCO-BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 14 GLOBAL CANCER BIOMARKERS FOR LUNG CANCER, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15 GLOBAL CANCER BIOMARKERS FOR BREAST CANCER, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16 GLOBAL CANCER BIOMARKERS FOR COLORECTAL CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 GLOBAL CANCER BIOMARKERS FOR PROSTATE CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 18 GLOBAL CANCER BIOMARKERS FOR STOMACH CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 19 GLOBAL CANCER BIOMARKERS FOR OTHER CANCERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 20 CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 21 DIAGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 22 DRUG DISCOVERY AND DEVELOPMENT MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 23 PROGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 24 RISK ASSESSMENT MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 25 OTHERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 26 CANCER BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 27 NORTH AMERICA CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 28 NORTH AMERICA CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 29 NORTH AMERICA CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 30 NORTH AMERICA CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 31 NORTH AMERICAN CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 32 EUROPEAN CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 33 EUROPEAN CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 34 EUROPEAN CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 35 EUROPEAN CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 36 EUROPEAN CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 37 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 38 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 39 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 40 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 41 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 42 LAMEA CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 43 LAMEA CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 44 LAMEA CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 45 LAMEA CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 46 LAMEA CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 47 ROCHE: COMPANY SNAPSHOT
TABLE 48 ABBOTT: COMPANY SNAPSHOT
TABLE 49 ABBOTT: OPERATING SEGMENTS
TABLE 50 GSK: COMPANY SNAPSHOT
TABLE 51 GSK: OPERATING SEGMENTS
TABLE 52 NOVARTIS: COMPANY SNAPSHOT
TABLE 53 NOVARTIS: OPERATING SEGMENTS
TABLE 54 MERCK: COMPANY SNAPSHOT
TABLE 55 MERCK: PRODUCT CATEGORIES
TABLE 56 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 57 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 58 ELI LILLY: OPERATING SEGMENTS
TABLE 59 PFIZER, INC.: COMPANY SNAPSHOT
TABLE 60 PFIZER, INC.: OPERATING SEGMENTS
TABLE 61 QIAGEN: COMPANY SNAPSHOT
TABLE 62 GENOMIC HEALTH: COMPANY SNAPSHOT
LIST OF FIGURE
FIG. 1 CANCER BIOMARKERS MARKET: SEGMENTATION
FIG. 2 TOP IMPACTING FACTORS: CANCER BIOMARKERS MARKET, 2015-2022
FIG. 3 PERCENTAGE (%) OF NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 4 TOP INVESTMENT POCKETS: CANCER BIOMARKERS, 2015-2022
FIG. 5 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION
FIG. 6 TOP WINNING STRATEGIES: NATURE & TYPE
FIG. 7 TYPES OF STRATEGIES DISTRIBUTION
FIG. 8 DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIG. 9 DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIG. 10 PORTERS FIVE FORCES ANALYSIS
FIG. 11 TOP PLAYER POSITIONING, 2015
FIG. 12 PATENTS REGISTERED/APPROVED IN THE WORLD, 2013-2016
FIG. 13 U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 14 EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 15 CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 16 CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 17 JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 18 OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 19 U.S.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 20 CANADA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 21 MEXICO: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 22 GERMANY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 23 U.K.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 24 FRANCE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 25 ITALY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 26 RUSSIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 27 REST OF EUROPE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 28 JAPAN: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 29 CHINA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 30 INDIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 31 AUSTRALIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 32 REST OF ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 33 BRAZIL: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 34 SAUDI ARABIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 35 UAE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 36 REST OF LAMEA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 37 ROCHE: NET SALES, 2013-2015 ($MILLION)
FIG. 38 ROCHE: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 39 ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 40 ROCHE: STRATEGY SHARE, 2014-2016 (%)
FIG. 41 ABBOTT: NET SALES, 2013-2015 ($MILLION)
FIG. 42 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIG. 43 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIG. 44 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 45 ABBOTT: STRATEGY SHARE, 2014-2016 (%)
FIG. 46 GSK: NET SALES, 2013-2015 ($MILLION)
FIG. 47 GSK: REVENUE, BY SEGMENT, 2015 (%)
FIG. 48 GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 49 GSK: STRATEGY SHARE, 2014-2016 (%)
FIG. 50 NOVARTIS: REVENUE, 2013-2015 ($MILLION)
FIG. 51 NOVARTIS: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 52 NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 53 NOVARTIS: STRATEGY SHARE, 2014-2016 (%)
FIG. 54 MERCK: NET SALES, 2013-2015 ($MILLION)
FIG. 55 MERCK: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 56 MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 57 MERCK: STRATEGY SHARE, 2014-2016 (%)
FIG. 58 BRISTOL-MYERS SQUIBB: NET SALES, 2013-2015 ($MILLION)
FIG. 59 BRISTOL-MYERS SQUIBB, REVENUE, BY GEOGRAPHY, 2015(%)
FIG. 60 BRISTOL-MYERS SQUIBB: STRATEGY SHARE, 2014-2016 (%)
FIG. 61 ELI LILLY: NET SALES, 2013-2015, ($MILLION)
FIG. 62 ELI LILLY: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 63 ELI LILLY: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 64 ELI LILLY: STRATEGY SHARE, 2014-2016 (%)
FIG. 65 PFIZER, INC.: NET SALES, 2013-2015, ($MILLION)
FIG. 66 PFIZER, INC.: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 67 PFIZER, INC.: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 68 PFIZER, INC.: STRATEGY SHARE, 2014-2016 (%)
FIG. 69 QIAGEN: NET SALES, 2013-2015, ($MILLION)
FIG. 70 QIAGEN: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 71 QIAGEN: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 72 QIAGEN: STRATEGY SHARE, 2014-2016 (%)
FIG. 73 GENOMIC HEALTH: NET SALES, 2013-2015 ($MILLION)
FIG. 74 GENOMIC HEALTH: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 75 GENOMIC HEALTH: STRATEGY SHARE, 2014-2016 (%)

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com